Autosomal Dominant Polycystic Kidney Disease Market Size is Set for Rapid Growth as Innovative Treatments and Rising Awareness Drive Demand by 2034

The Autosomal Dominant Polycystic Kidney Disease market size is expected to increase during the forecast period with the increasing prevalence, disease awareness, and promising emerging treatment options by leading companies such as Otsuka Pharmaceutical, Sanofi, Reata Pharmaceuticals, Galapagos NV, Janssen Pharmaceuticals, Regulus Therapeutics, Xortx Therapeutics

[Nevada, United States] - DelveInsight's "Autosomal Dominant Polycystic Kidney Disease Market Insights, Epidemiology, and Market Forecast 2034." report offers a detailed examination of Autosomal Dominant Polycystic Kidney Disease, covering historical and predicted epidemiology, market trends, and treatment scenarios in the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

To Know in detail about the Autosomal Dominant Polycystic Kidney Disease Market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; https://www.delveinsight.com/report-store/autosomal-dominant-polycystic-kidney-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Key Findings from the Autosomal Dominant Polycystic Kidney Disease Market Report:
The Autosomal Dominant Polycystic Kidney Disease market size is poised for significant growth, with an anticipated Compound Annual Growth Rate (CAGR) during the study period (2020-2034).
In June, 2024: Hannover announced that the EMPA-PKD trial is assessing the safety of empagliflozin in patients with rapid progressive ADPKD with and without concomitant tolvaptan use by monitoring kidney growth and the rate of loss of kidney function.
In March, 2024: Rege Nephro Co., Ltd. announced a Phase IIa Clinical Trial of Tamibarotene in Patients With Autosomal Dominant Polycystic Kidney Disease
In February, 2024: Reata announced that an open-label Phase 2 trial will study the safety, tolerability, and efficacy of bardoxolone methyl in qualified patients with the following rare chronic kidney diseases (CKD): CKD associated with type 1 diabetes (T1D), IgA nephropathy (IgAN), focal segmental glomerulosclerosis (FSGS), and autosomal dominant polycystic kidney disease (ADPKD).
Total diagnosed prevalent cases of ADPKD in the 7MM were found to be approximately 367,042 cases in the year 2021. The diagnosed prevalent cases of ADPKD are expected to rise by 2032
In 2021, the total diagnosed prevalent cases of ADPKD in EU-5 countries were observed to be about 193,161 cases which are expected to change by 2032.
The United States accounted for approximately 142,709 diagnosed prevalent cases of ADPKD in 2021
It was observed that in the US, ADPKD was most prevalent in 44-64 years age group. The ADPKD cases for 5, 5-14, 15-24, 25-44, 45-64, 65 years of age were approximately 1,142, 3,996, 9,562, 44,953,56,513,and 26,544 cases, respectively in 2021 which are expected to increase by 2032.
Key Autosomal Dominant Polycystic Kidney Disease Companies are as follows: Otsuka Pharmaceutical, Sanofi, Reata Pharmaceuticals, Galapagos NV, Janssen Pharmaceuticals, Regulus Therapeutics, Xortx Therapeutics
Key Autosomal Dominant Polycystic Kidney Disease Therapies are as follow: JYNARQUE/ JINARC/SAMSCA (tolvaptan), RGLS8429, XRx-008, VX-407, Empagliflozin, Bosutinib, Lixivaptan, Tesevatinib, Everolimus, OPC-41061, Tamibarotene
Launching multiple stage Autosomal Dominant Polycystic Kidney Disease pipeline products is expected to revolutionize market dynamics, further propelling market growth.

Dive into our detailed Autosomal Dominant Polycystic Kidney Disease market research report to uncover actionable insights, industry forecasts, and competitive analysis @ https://www.delveinsight.com/sample-request/autosomal-dominant-polycystic-kidney-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Autosomal Dominant Polycystic Kidney Disease Overview:
Polycystic kidney disease (PKD) is an inherited genetic disorder where fluid-filled sacs, called cysts, develop in the kidneys.Unlike simple kidney cysts that are harmless, cysts in PKD enlarge the kidneys, changing their shape and interfering withtheir ability to filter waste products from the blood. It reduces kidney function eventually leading to kidney failure. Cystsmay also develop in other organs besides the kidney, particularly the liver, pancreas, spleen, ovaries, and large bowel.

Autosomal Dominant Polycystic Kidney Disease Epidemiology Segmentation:
The Autosomal Dominant Polycystic Kidney Disease market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
Autosomal Dominant Polycystic Kidney Disease Total Diagnosed Prevalent Cases
Autosomal Dominant Polycystic Kidney Disease Mutation-specific Cases
Autosomal Dominant Polycystic Kidney Disease Age-specific Cases

For more information about Autosomal Dominant Polycystic Kidney Disease companies working in the treatment market, visit https://www.delveinsight.com/sample-request/autosomal-dominant-polycystic-kidney-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Autosomal Dominant Polycystic Kidney Disease Market Insights
At present, there is no cure for PKD. However, a lot of research is being done. Recent studies suggest that drinking plain water throughout the day and avoiding caffeine in beverages can slow the growth of cysts. Research is alsohelping us understand the genetic basis of PKD.
The treatment of individuals with ADPKD involves detailed attention to diet, fluid intake, blood pressure control,and avoiding harmful drug and lifestyle choices. Implementation of these measures early in the disease shouldslow the progression of kidney (renal) disease and preserve kidney function to some extent.
Antibiotics like ciprofloxacin, levofloxacin, trimethoprim-sulfamethoxazole, clindamycin, chloramphenicol, andothers, and phosphate binders like calcium acetate, lanthanum carbonate, sevelamer hydrochloride, and othersare also involved in the treatment of ADPKD.

Autosomal Dominant Polycystic Kidney Disease Drugs Uptake
Tesevatinib is an oral small molecule tyrosine kinase inhibitor targeting the epidermal growth factor receptor (EGF receptor), a part of signaling pathways known to promote cyst growth in ADPKD. Tesevatinib accumulates in the kidneys, 15-fold greater than in the blood. Tesevatinib has been demonstrated to inhibit the growth of kidneys and preserve kidney function in PKD animal models
Bardoxolone methyl is an investigational, once-daily, orally administered Nuclear erythroid 2-related factor (Nrf2) activator. In ADPKD, inflammation and mitochondrial dysfunction, processes known to be suppressed by Nrf2 activation, drive cyst growth in the kidney tubules
GLPG2737 is a Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) inhibitor observed to be well tolerated by patients in previous clinical trials. It is hypothesized that inhibition of the CFTR channel might reduce cyst growth and enlargement in patients with ADPKD
AT-20494 is an orally bioavailable small molecule that selectively inhibits the activity of mTORC1, the master modulator of cellular metabolism, which is overactive in multiple chronic diseases, including autosomal dominant polycystic kidney diseases.
RGLS8429 is a novel, next-generation oligonucleotide for the treatment of ADPKDdesigned to inhibit miR-17 and preferentially target the kidney. Administration of RGLS8429 has shown robust data in preclinical models, where clear improvements in kidney function, size, and other measures of disease severity and a superior pharmacologic profile, have been demonstrated along with a superior pharmacologic profile in preclinical studies compared to Regulus

Dive into our comprehensive market research report to discover in-depth insights, emerging trends, and strategic opportunities @ https://www.delveinsight.com/sample-request/autosomal-dominant-polycystic-kidney-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Autosomal Dominant Polycystic Kidney Disease Therapies and Key Companies:
JYNARQUE/ JINARC/SAMSCA (tolvaptan): Otsuka America Pharmaceutical
RGLS8429: Regulus Therapeutics
XRx-008: Xortx Therapeutics
VX-407: Vertex Pharmaceuticals
Empagliflozin: Hannover Medical School
Bosutinib: Pfizer
Lixivaptan: Palladio Biosciences
Tesevatinib: Kadmon, a Sanofi Company
Everolimus: Novartis Pharmaceuticals
OPC-41061: Otsuka Pharmaceutical Co., Ltd.
Tamibarotene: Rege Nephro Co., Ltd.

Autosomal Dominant Polycystic Kidney Disease Epidemiology:
Autosomal Dominant Polycystic Kidney Disease (ADPKD) is one of the most common inherited kidney disorders globally, affecting approximately 1 in 400 to 1,000 people. This progressive genetic condition is primarily characterized by the development of multiple cysts in both kidneys, leading to end-stage renal disease (ESRD) in nearly half of the patients by the age of 60. The disease is caused by mutations in the PKD1 and PKD2 genes.

Seize Market Opportunities with Our Expert Analysis! Our report delivers valuable insights into market dynamics, key players, and emerging trends @ https://www.delveinsight.com/sample-request/autosomal-dominant-polycystic-kidney-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Autosomal Dominant Polycystic Kidney Disease Market Drivers:
Increasing Prevalence
Rising Awareness and Genetic Screening
Technological Advancements
Advanced Therapeutic Options

Autosomal Dominant Polycystic Kidney Disease Market Barriers:
High Treatment Costs
Limited Availability of Curative Therapies
Complexity in Drug Development
Low Awareness in Emerging Markets

Stay Ahead in a Competitive Landscape with Our Exhaustive Market Research Report-Dive Into Detailed Analysis, Key Trends, and Future Projections @ https://www.delveinsight.com/sample-request/autosomal-dominant-polycystic-kidney-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Scope of the Autosomal Dominant Polycystic Kidney Disease Market Report:
Study Period: 2020-2034
Coverage: 7MM (The United States, EU5, and Japan)
Key Autosomal Dominant Polycystic Kidney Disease Companies: Otsuka Pharmaceutical, Sanofi, Reata Pharmaceuticals, Galapagos NV, Janssen Pharmaceuticals, Regulus Therapeutics, Xortx Therapeutics
Key Autosomal Dominant Polycystic Kidney Disease Therapies: JYNARQUE/ JINARC/SAMSCA (tolvaptan), RGLS8429, XRx-008, VX-407, Empagliflozin, Bosutinib, Lixivaptan, Tesevatinib, Everolimus, OPC-41061, Tamibarotene
Autosomal Dominant Polycystic Kidney Disease Therapeutic Assessment: Current marketed and emerging therapies
Autosomal Dominant Polycystic Kidney Disease Market Dynamics: Autosomal Dominant Polycystic Kidney Disease Market drivers and Autosomal Dominant Polycystic Kidney Disease barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Autosomal Dominant Polycystic Kidney Disease Unmet Needs: Insights into unmet needs, KOL's views, Analyst's views, Market Access, and Reimbursement.

To access the full report and gain a deeper understanding of Autosomal Dominant Polycystic Kidney Disease market outlook, drug uptake, treatment scenario, and epidemiology trends, https://www.delveinsight.com/sample-request/autosomal-dominant-polycystic-kidney-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Table of Content:

1 Key Insights
2 Report Introduction
3 ADPKD Market Overview at a Glance
4 ADPKD Market: Future Perspective
5 Executive Summary of ADPKD
6 Key Events
7 Disease Background and Overview
8 Epidemiology and Patient Population
9 Patient Journey
10 Marketed Drugs
11 Emerging Drugs
12 Autosomal Dominant Polycystic Kidney Disease: 7MM Analysis
13 Key Opinion Leader's Views
14 SWOT Analysis
15 Unmet Needs
16 Reimbursement and Market Access
17 Appendix
18 DelveInsight Capabilities
19 Disclaimer
20 About DelveInsight

About DelveInsight:
DelveInsight is a leading market research firm providing insightful solutions and services to pharmaceutical and life sciences companies. With a commitment to delivering accurate and comprehensive reports, DelveInsight empowers businesses to make informed decisions and navigate the complexities of the healthcare industry.

Contact Information:
Company Name: DelveInsight Business Research LLP
Contact Person: Ram Kapoor
Email: info@delveinsight.com
Contact No.: +91-9650213330
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

This release was published on openPR.